G71.033

Clinical Causes: Inherited genetic mutations affecting the DYSF gene, which encodes the dysferlin protein. Autosomal recessive inheritance pattern, meaning a person must inherit two copies of the faulty gene, one from each parent. No known environmental or lifestyle factors directly cause this condition, though genetic predisposition plays a central role.

Key Symptoms: Gradual muscle weakness primarily in the hips, pelvis, shoulders, and thighs. Difficulty climbing stairs, rising from a seated position, or lifting objects. Muscle wasting or thinning in affected areas. Potential calf muscle hypertrophy in early stages. In some cases, the progression may include the development of weakness in distal muscles, such as those in the lower legs. In Miyoshi Myopathy, initial symptoms often involve weakness in the calves, leading to trouble walking or standing on tiptoes.

Diagnosis Path: Diagnosis involves a combination of clinical evaluation, family history, and specialized tests, including: - Blood tests showing elevated levels of muscle enzymes, such as creatine kinase (CK). - Electromyography (EMG) to assess muscle activity. - Muscle biopsy to examine muscle tissue for characteristic signs of dystrophy. - Genetic testing to identify mutations in the DYSF gene, confirming the diagnosis of dysferlinopathy.

Treatment Protocols: Currently, there is no cure for limb girdle muscular dystrophy due to dysferlin dysfunction. Management focuses on supportive care and maintaining quality of life, including: - Physical therapy to improve strength and flexibility. - Occupational therapy to assist with daily activities. - Use of assistive devices, such as braces or walkers, to aid mobility. - Regular monitoring of respiratory and cardiac functions, as these can be affected in advanced stages. - Participation in clinical trials exploring potential therapies is encouraged for future treatment options. - Nutritional support and energy conservation techniques to reduce fatigue and optimize health.